Johnson & Johnson (JNJ) – Undervalued Pharma Leader Offers Defensive Upside Amid Sector Selloff, Jim Cramer Backs Staggered Entry - Cash Flow Report

Live News

As of April 23, 2026, 11:54 UTC, Johnson & Johnson (NYSE: JNJ) was featured as a top bullish pick on Jim Cramer’s *Mad Money* program, with Cramer announcing that his Charitable Trust had initiated a position in the stock during the ongoing sector-wide pullback. Cramer noted that pharma is currently deeply out of favor with market participants, who have rotated heavily into high-growth AI and cyclical industrial names so far this year, creating a rare opportunity to buy high-quality healthcare a Johnson & Johnson (JNJ) – Undervalued Pharma Leader Offers Defensive Upside Amid Sector Selloff, Jim Cramer Backs Staggered EntryAccess to futures, forex, and commodity data broadens perspective. Traders gain insight into potential influences on equities.Many investors underestimate the psychological component of trading. Emotional reactions to gains and losses can cloud judgment, leading to impulsive decisions. Developing discipline, patience, and a systematic approach is often what separates consistently successful traders from the rest.Johnson & Johnson (JNJ) – Undervalued Pharma Leader Offers Defensive Upside Amid Sector Selloff, Jim Cramer Backs Staggered EntryPredictive analytics are increasingly used to estimate potential returns and risks. Investors use these forecasts to inform entry and exit strategies.

Key Highlights

1. **Valuation Profile**: JNJ currently trades at 13.2x forward 12-month price-to-earnings (P/E), a 22% discount to its 5-year historical average of 16.9x, and an 18% discount to the large-cap pharma peer group average of 16.1x. The stock also offers a 3.1% annual dividend yield, with 59 consecutive years of dividend increases, earning it Dividend King status, one of only 48 U.S. public companies to hold the designation. 2. **Icotyde Catalyst**: Consensus sell-side estimates project Icotyde will Johnson & Johnson (JNJ) – Undervalued Pharma Leader Offers Defensive Upside Amid Sector Selloff, Jim Cramer Backs Staggered EntrySome investors rely on sentiment alongside traditional indicators. Early detection of behavioral trends can signal emerging opportunities.Combining global perspectives with local insights provides a more comprehensive understanding. Monitoring developments in multiple regions helps investors anticipate cross-market impacts and potential opportunities.Johnson & Johnson (JNJ) – Undervalued Pharma Leader Offers Defensive Upside Amid Sector Selloff, Jim Cramer Backs Staggered EntryReal-time tracking of futures markets can provide early signals for equity movements. Since futures often react quickly to news, they serve as a leading indicator in many cases.

Expert Insights

Cramer’s bullish call on JNJ aligns with core portfolio construction principles he cited from his tenure at Goldman Sachs, noting that “assets do not appreciate in unison, and defensive exposure is critical to mitigating drawdowns in growth-heavy portfolios.” With a 5-year beta of 0.62, JNJ is 38% less volatile than the broader S&P 500, making it an ideal hedge for investors holding concentrated positions in high-beta AI and tech stocks that have led 2026 market gains. That said, investors should weigh material downside risks before initiating a position. JNJ’s top-selling immunology drug Stelara loses U.S. exclusivity in 2027, with consensus estimates projecting the loss of $2.1 billion in annual revenue by 2028 before Icotyde and other pipeline assets can offset the decline. Additionally, proposed U.S. drug pricing reforms could compress margins for JNJ’s top 10 selling products by an estimated 7% to 9% if passed in their current form. Consensus analyst ratings remain largely bullish on JNJ, with 18 of 24 covering analysts assigning a Buy or Strong Buy rating, and a weighted average 12-month price target of $187, implying 21% upside from JNJ’s April 23 closing price of $154.50. For investors seeking higher short-term upside, as noted in recent market analysis, select undervalued AI plays positioned to benefit from onshoring trends and Trump-era tariff policies may offer higher risk-adjusted returns, though these assets carry far higher volatility and drawdown risk than JNJ. Overall, JNJ represents a high-quality defensive play for long-term investors with moderate risk tolerance, and the current sector selloff offers a rare entry point to one of the U.S.’s most consistent operational performers. For growth-focused investors, a 5% to 10% portfolio allocation to JNJ can provide meaningful downside protection without sacrificing long-term total return potential, balancing exposure to high-growth segments that dominate current market momentum. (Word count: 1172) Disclosure: No holdings in JNJ or mentioned AI securities as of publication. Johnson & Johnson (JNJ) – Undervalued Pharma Leader Offers Defensive Upside Amid Sector Selloff, Jim Cramer Backs Staggered EntryInvestors often monitor sector rotations to inform allocation decisions. Understanding which sectors are gaining or losing momentum helps optimize portfolios.Some traders combine sentiment analysis from social media with traditional metrics. While unconventional, this approach can highlight emerging trends before they appear in official data.Johnson & Johnson (JNJ) – Undervalued Pharma Leader Offers Defensive Upside Amid Sector Selloff, Jim Cramer Backs Staggered EntryProfessionals emphasize the importance of trend confirmation. A signal is more reliable when supported by volume, momentum indicators, and macroeconomic alignment, reducing the likelihood of acting on transient or false patterns.